Show simple item record

dc.contributor.authorCornberg, Markus
dc.contributor.authorButi, Maria
dc.contributor.authorEberhardt, Christiane S
dc.contributor.authorGrossi, Paolo Antonio
dc.contributor.authorShouval, Daniel
dc.date.accessioned2021-03-04T14:35:19Z
dc.date.available2021-03-04T14:35:19Z
dc.date.issued2021-02-06
dc.identifier.citationJ Hepatol. 2021 Feb 6:S0168-8278(21)00081-7. doi: 10.1016/j.jhep.2021.01.032. Epub ahead of print.en_US
dc.identifier.pmid33563499
dc.identifier.doi10.1016/j.jhep.2021.01.032
dc.identifier.urihttp://hdl.handle.net/10033/622772
dc.description.abstractAccording to a recent World Health Organization estimate, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, which originated in China in 2019, has spread globally, infecting nearly 100 million people worldwide by January 2021. Patients with chronic liver diseases (CLD), particularly cirrhosis, hepatobiliary malignancies, candidates for liver transplantation, and immunosuppressed individuals after liver transplantation appear to be at increased risk of infections in general, which in turn translates into increased mortality. This is also the case for SARS-CoV-2 infection, where patients with cirrhosis, in particular, are at high risk of a severe COVID-19 course. Therefore, vaccination against various pathogens including SARS-CoV-2, administered as early as possible in patients with CLD, is an important protective measure. However, due to impaired immune responses in these patients, the immediate and long-term protective response through immunisation may be incomplete. The current SARS-CoV-2 pandemic has led to the exceptionally fast development of several vaccine candidates. A small number of these SARS-CoV-2 vaccine candidates have already undergone phase III, placebo-controlled, clinical trials in healthy individuals with proof of short-term safety, immunogenicity and efficacy. However, although regulatory agencies in the US and Europe have already approved some of these vaccines for clinical use, information on immunogenicity, duration of protection and long-term safety in patients with CLD, cirrhosis, hepatobiliary cancer and liver transplant recipients has yet to be generated. This review summarises the data on vaccine safety, immunogenicity, and efficacy in this patient population in general and discusses the implications of this knowledge on the introduction of the new SARS-CoV-2 vaccines.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867401/en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCOVID-19en_US
dc.subjectCirrhosisen_US
dc.subjectInfluenzaen_US
dc.subjectLiver transplantationen_US
dc.subjectSARS-CoV-2en_US
dc.subjectVaccineen_US
dc.titleEASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.en_US
dc.typeArticleen_US
dc.identifier.eissn1600-0641
dc.contributor.departmentCiiM, Zentrum für individualisierte Infektionsmedizin, Feodor-Lynen-Str.7, 30625 Hannover.en_US
dc.identifier.journalJournal of hepatologyen_US
dc.identifier.pmcidPMC7867401
refterms.dateFOA2021-03-04T14:35:19Z
dc.source.journaltitleJournal of hepatology
dc.source.countryNetherlands


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
Cornberg et al.pdf
Size:
553.4Kb
Format:
PDF
Description:
free copy from the Elsevier ...

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International